Significant correlation between relieving of non-alcoholic fatty liver disease and regulation on gut microbiota and short-chain fatty acids in mice by Lactobacillus reuteri CCFM8631
JIAO Ting1, ZHU Huiyue1, SI Qian1, XU Mengshu1, SUN Shanshan1, MA Fangli2*, WANG Gang1*, ZHAO Jianxin1, ZHANG Hao1, CHEN Wei1
1(School of Food Science and Technology, Jiangnan University, Wuxi 214122, China) 2(Infinitus (China) Company Ltd., Guangzhou 510623, China)
Abstract: In order to investigate the effects of different lactic acid bacteria (LAB) on the progression of non-alcoholic fatty liver disease (NAFLD) in mice which was induced by a high-fat and high-cholesterol diet (HFHCD), 4-week-old C57BL/6J mice were fed with HFHCD while administrated different LAB for 23 weeks. At the end of experiment, the blood lipid, blood glucose, liver inflammation, liver damage, fecal short-chain fatty acids (SCFAs), and gut microbiota were evaluated. It was showed that LAB supplementation prevented abnormal weight gain and liver damage induced by HFHCD, while showing different effects on the blood lipid and blood glucose regulation. Among all the strains, Lactobacillus reuteri CCFM8631 showed the highest capacity in alleviation of NAFLD. Furthermore, at the end of the treatment, the fecal SCFAs content and the abundance of Bifidobacterium, Lactobacillus, and Desulfovibrio significantly increased, whilst the abundance of Mucispirillum, Turicibacter, SMB53, and Allobaculum were significantly reduced. Correlation analysis between intestinal and liver pathological indicators showed that regulation on the SCFAs and gut microbiota was significantly associated with NAFLD alleviation. Therefore, the regulation on the SCFAs and gut microbiota by Lactobacillus reuteri CCFM8631 may be an important way for it to relieve NAFLD. This study provides a reference for the preparation of probiotic products in NAFLD prevention. This study provides a new option for the prevention and treatment of NAFLD. Also, it provides a reference for the development of probiotic preparations for NAFLD.
焦婷,朱慧越,司倩,等. 罗伊氏乳杆菌CCFM8631缓解小鼠非酒精性脂肪性肝病与其对肠道菌群及短链脂肪酸的调节显著相关[J]. 食品与发酵工业, 2020, 46(10): 35-43.
JIAO Ting,ZHU Huiyue,SI Qian,et al. Significant correlation between relieving of non-alcoholic fatty liver disease and regulation on gut microbiota and short-chain fatty acids in mice by Lactobacillus reuteri CCFM8631[J]. Food and Fermentation Industries, 2020, 46(10): 35-43.
LI J, ZOU B, YEO Y H, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: A systematic review and meta-analysis[J]. The Lancet Gastroenterology & Hepatology, 2019, 4(5): 389-398.
[2]
XIE C, YAGAI T, LUO Y, et al. Activation of intestinal hypoxia-inducible factor 2alpha during obesity contributes to hepatic steatosis[J]. Nat Med, 2017, 23(11): 1 298-1 308.
[3]
WESOLOWSKI S R, KASMI K C, JONSCHER K R, et al. Developmental origins of NAFLD: A womb with a clue[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(2): 81-96.
JIANG W, WU N, WANG X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease[J]. Sci Rep, 2015(5):8 096.
[6]
LEUNG C, RIVERA L R, FURNESS J B, et al. The role of the gut microbiota in NAFLD[J]. Nature Reviews Gastroenterology & Hepatology, 2016,13(7):412-425.
[7]
LEUNG C, RIVERA L, FURNESS J B, et al. The role of the gut microbiota in NAFLD[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(7): 412-425.
[8]
TILG H, CANI P D, MAYER E A. Gut microbiome and liver diseases[J]. Gut, 2016, 65(12): 2 035-2 044.
[9]
MIHAILOVIC' M, ZˇIVKOVIC' M, JOVANOVIC' J A, et al. Oral administration of probiotic Lactobacillus paraplantarum BGCG11 attenuates diabetes-induced liver and kidney damage in rats[J]. Journal of Functional Foods, 2017(38):427-437.
BEDOSSA P, CONSORTIUM F P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease[J]. Hepatology, 2014, 60(2): 565-575.
[14]
WANG G, XU Q, JIN X, et al. Effects of lactobacilli with different regulatory behaviours on tight junctions in mice with dextran sodium sulphate-induced colitis[J]. Journal of Functional Foods, 2018:47:107-115.
[15]
WANG L, PAN M, LI D, et al. Metagenomic insights into the effects of oligosaccharides on the microbial composition of cecal contents in constipated mice[J]. Journal of Functional Foods, 2017,38(PartA):486-496.
LIN H V, FRASSETTO A, KOWALIK E J J R, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms[J]. PLoS One, 2012, 7(4): 35 240.
[20]
GAO Z, YIN J, ZHANG J, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice[J]. Diabetes, 2009, 58(7): 1 509-1 517.
[21]
ZHOU D, CHEN Y W, ZHAO Z H, et al. Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression[J]. Exp Mol Med, 2018, 50(12): 157.
DEL CHIERICO F, NOBILI V, VERNOCCHI P, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach[J]. Hepatology, 2017, 65(2): 451-464.
[24]
SHIN N-R, WHON T W, BAE J W. Proteobacteria: microbial signature of dysbiosis in gut microbiota[J]. Trends in Biotechnology, 2015, 33(9): 496-503.
[25]
DIN A U, HASSAN A, ZHU Y, et al. Inhibitory effect of Bifidobacterium Bifidum ATCC 29521 on colitis and its mechanism[J]. The Journal of Nutritional Biochemistry, 2020,79: 108 353.
WAN P, PENG Y, CHEN G, et al. Modulation of gut microbiota by Ilex kudingcha improves dextran sulfate sodium-induced colitis[J]. Food Research International, 2019, 126:108 595.
[28]
WAN X Z, LI T T, ZHONG R T, et al. Anti-diabetic activity of PUFAs-rich extracts of Chlorella pyrenoidosa and Spirulina platensis in rats[J]. Food and Chemical Toxicology, 2019, 128:233-239.
[29]
HUANG K, YU W, LI S, et al. Effect of embryo-remaining oat rice on the lipid profile and intestinal microbiota in high-fat diet fed rats[J]. Food Research International, 2020, 129:108 816.
[30]
MASANORI H, TAKAMASA M, SATOMI H, et al. Comparative analysis of the intestinal flora in type 2 diabetes and nondiabetic mice[J].Experimental animals, 2017, 66(4):405-416.
[31]
ZHU W, GREGORY J C, ORG E, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk[J]. Cell, 2016, 165(1): 111-124.
[32]
TAN X, LIU Y, LONG J, et al. Trimethylamine N-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease[J]. Molecular Nutrition & Food Research, 2019, 63(17): 1 900 257.
2020, Vol. 46 
